Case Report
BibTex RIS Cite

Dabigatrana bağlı özofagus ülseri

Year 2017, Volume: 25 Issue: 2, 47 - 48, 29.08.2017
https://doi.org/10.17940/endoskopi.339868

Abstract

Dabigatran trombin inhibisyonu yaparak antikoagülan etki gösteren bir ön ilaçtır. Rutin labovatuar takibi ve doz titrasyonu gerektirmemesi varfarine göre kullanım avantajı sağlanken, gastrointestinal sistem üzerine daha sık yan etki oluşturması önde gelen dezavantajlarındandır. Bizim vakamız, dabigatran kullanımına bağlı gelişen özofagus ülser hastasıdır.


References

  • 1. Kim SH, Jeong JB, Kim JW, Koh SJ, Kim BG, Lee KL, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. World journal of gastroenterology. [Multicenter Study Observational Study]. 2014 Aug 21;20(31):10994-9. 2. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. [Clinical Trial Research Support, Non-U.S. Gov't]. 2013 Mar;11(3):246-52 e1-5. 3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2009 Sep 17;361(12):1139-51. 4. Shibagaki K, Taniguchi H, Goto D, Kobayashi K, Kinoshita Y. Dabigatran-induced asymptomatic esophageal mucosal injury. Gastrointest Endosc. [Case Reports]. 2016 Feb;83(2):472-3; discussion 4. 5. Liu E, Shehata M, Liu T, Amorn A, Cingolani E, Kannarkat V, et al. Prevention of esophageal thermal injury during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. [Review]. 2012 Oct;35(1):35-44. 6. Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatol. [Case Reports]. 2014 Jul;12(7):e55-6. 7. Toya Y, Nakamura S, Tomita K, Matsuda N, Abe K, Abiko Y, et al. Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016 Mar;31(3):610-4.

Dabigatran-induced esophageal ulcer

Year 2017, Volume: 25 Issue: 2, 47 - 48, 29.08.2017
https://doi.org/10.17940/endoskopi.339868

Abstract

Dabigatran,
which has an anticoagulant effect by inhibiting the action of thrombin, is a
prodrug. An advantage of this drug over warfarin is that it does not require
routine laboratory monitoring and dose adjustments. However, adverse effects on
the gastrointestinal system are more common in patients using dabigatran than
in patients using warfarin. In the present study, we report a case of
dabigatran-induced esophageal ulcer.

References

  • 1. Kim SH, Jeong JB, Kim JW, Koh SJ, Kim BG, Lee KL, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. World journal of gastroenterology. [Multicenter Study Observational Study]. 2014 Aug 21;20(31):10994-9. 2. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. [Clinical Trial Research Support, Non-U.S. Gov't]. 2013 Mar;11(3):246-52 e1-5. 3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2009 Sep 17;361(12):1139-51. 4. Shibagaki K, Taniguchi H, Goto D, Kobayashi K, Kinoshita Y. Dabigatran-induced asymptomatic esophageal mucosal injury. Gastrointest Endosc. [Case Reports]. 2016 Feb;83(2):472-3; discussion 4. 5. Liu E, Shehata M, Liu T, Amorn A, Cingolani E, Kannarkat V, et al. Prevention of esophageal thermal injury during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. [Review]. 2012 Oct;35(1):35-44. 6. Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatol. [Case Reports]. 2014 Jul;12(7):e55-6. 7. Toya Y, Nakamura S, Tomita K, Matsuda N, Abe K, Abiko Y, et al. Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016 Mar;31(3):610-4.
There are 1 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Articles
Authors

Hakan Ümit Ünal This is me 0000-0003-1415-0416

Özlem Saygılı This is me 0000-0001-5618-9533

Murat Saruç 0000-0002-9541-0381

Publication Date August 29, 2017
Published in Issue Year 2017 Volume: 25 Issue: 2

Cite

APA Ünal, H. Ü., Saygılı, Ö., & Saruç, M. (2017). Dabigatrana bağlı özofagus ülseri. Endoskopi Gastrointestinal, 25(2), 47-48. https://doi.org/10.17940/endoskopi.339868
AMA Ünal HÜ, Saygılı Ö, Saruç M. Dabigatrana bağlı özofagus ülseri. Endoskopi Gastrointestinal. August 2017;25(2):47-48. doi:10.17940/endoskopi.339868
Chicago Ünal, Hakan Ümit, Özlem Saygılı, and Murat Saruç. “Dabigatrana bağlı özofagus ülseri”. Endoskopi Gastrointestinal 25, no. 2 (August 2017): 47-48. https://doi.org/10.17940/endoskopi.339868.
EndNote Ünal HÜ, Saygılı Ö, Saruç M (August 1, 2017) Dabigatrana bağlı özofagus ülseri. Endoskopi Gastrointestinal 25 2 47–48.
IEEE H. Ü. Ünal, Ö. Saygılı, and M. Saruç, “Dabigatrana bağlı özofagus ülseri”, Endoskopi Gastrointestinal, vol. 25, no. 2, pp. 47–48, 2017, doi: 10.17940/endoskopi.339868.
ISNAD Ünal, Hakan Ümit et al. “Dabigatrana bağlı özofagus ülseri”. Endoskopi Gastrointestinal 25/2 (August 2017), 47-48. https://doi.org/10.17940/endoskopi.339868.
JAMA Ünal HÜ, Saygılı Ö, Saruç M. Dabigatrana bağlı özofagus ülseri. Endoskopi Gastrointestinal. 2017;25:47–48.
MLA Ünal, Hakan Ümit et al. “Dabigatrana bağlı özofagus ülseri”. Endoskopi Gastrointestinal, vol. 25, no. 2, 2017, pp. 47-48, doi:10.17940/endoskopi.339868.
Vancouver Ünal HÜ, Saygılı Ö, Saruç M. Dabigatrana bağlı özofagus ülseri. Endoskopi Gastrointestinal. 2017;25(2):47-8.